Summary: More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. Since the JOBS Act passed, attention has focused mostly on the law’s effects on the IPO market. This is largely because the IPO On-Ramp was the Read More
